Status:
COMPLETED
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Huntington's Disease
Eligibility:
All Genders
26+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's D...
Detailed Description
Extensive evidence exists that neurodegeneration begins many years before HD can be diagnosed clinically. Therefore, it is most desirable to begin a neuroprotective therapy before or during this prema...
Eligibility Criteria
Inclusion
- Individuals who have completed the Pre-CREST Study.
- Individuals capable of providing independent informed consent and complying with trial procedures.
Exclusion
- Clinical evidence of unstable medical or psychiatric illness in the investigator's judgment.
- Additional eligibility criteria apply.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01411163
Start Date
April 1 2010
End Date
May 1 2013
Last Update
February 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129